A stock in confusion awaiting Q2 results for clear trend

The amount of time GLS is spending consolidating between 600 and 660 leads me to believe that this is an important resistance zone and therefore I am preparing my interim chai cup here... If it breaks out upward of this zone, my final target would be 906 (638+268).. there are numerous resistances coming up at 675/725/799, each of would also be minor targets but the consolidation at the current level may be that big tug of war before a strong breach on either side ...

915 and 1064 are the 1.272 & 1.618 fibonacci levels 635 and 584 are the 0.618 & 0.5 fibonacci levels. Stop loss is 595

Threats are inconsistent topline, gross margins and pending USFDA plant inspections. Tailwinds are capex increase, strong generic US market and continued robust business from parent Glenmark Pharma.

Disclosure: Invested